There is a significant group of endometrial carcinomas (grade 1/2 endometrioid, MMR proficient, p53 wild‐type, stage IA, estrogen receptor (ER) positive, no substantial LVSI) where adjuvant treatment will not be given and it could be argued that in these cases POLE testing is not necessary. The gene discussed is ESR1; the disease is endometrial carcinoma.